Read more

May 21, 2021
2 min watch
Save

VIDEO: Phase 3 data on deucravacitinib 'quite compelling'

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

In this video, Joel M. Gelfand, MD, MSCE, professor of dermatology and epidemiology at the University of Pennsylvania Perelman School of Medicine, spoke with Healio about research on deucravacitinib presented at AAD VMX 2021.

In a phase 3 randomized placebo-controlled trial, researchers found that more patients with plaque psoriasis who received deucravacitinib achieved Psoriasis Area and Severity Index 75 at week 16 compared with those who received Otezla (apremilast, Amgen).

Gelfand said that these findings showed that deucravacitinib demonstrated “strong efficacy for an oral medication.”

He also noted that the safety data for the oral TYK2 inhibitor was “quite compelling.”

While 22% to 26% of patients who received apremilast experienced diarrhea and nausea, Gelfand said, just 2% to 7% of those who received deucravacitinib experienced these adverse effects.

Gelfand added that a small percentage of patients in the deucravacitinib group developed folliculitis or acne, but noted that these symptoms are “usually pretty benign and [don’t] cause discontinuation of the medication.”